CMT Research Foundation Targets CMT1X in Partnership with University of Illinois Chicago
The CMT Research Foundation is partnering with the University of Illinois Chicago to test a potential therapeutic for CMT1X, the second most common form of CMT, behind only CMT1A in prevalence. CMT is one of the most common inherited neurological disorders, affecting...CMT Research Foundation partners with Biotechnology Company AcuraStem and CMT Researcher Alessandra Bolino to test new drug in CMT4B1
The CMT Research Foundation is proud to announce our latest project, a partnership between AcuraStem, a patient-based drug discovery platform company, and Dr. Alessandra Bolino, a renowned expert in CMT and the head of the Human Inherited Neuropathies Unit at the...Targeting Axon Degeneration – a treatment for all types of CMT?
Can axon degeneration be prevented in CMT? By Dr. Grace Pavlath, PhD I’m often asked if a therapy for one type of CMT could be beneficial in another. There are over 100 different genes known to cause CMT; they either directly disrupt myelin or axon integrity of...AcuraStem Achieves First Milestone
Just nine months ago, we announced a milestone-based, research collaboration with AcuraStem to test thousands of compounds aimed at producing effective treatments for CMT2A. We are very pleased to report that AcuraStem has completed phase one of the CMT2A project. To...CMT1B project is funded & ready for take off!
Paving pathways for mission critical projects CMT Research Foundation is partnering with Dr. Maurizio D’Antonio of I.R.C.C.S. Ospedale San Raffaele, in Milan, Italy to fund the lab’s research of Myelin Protein Zero (MPZ), the gene associated with CMT1B. Dr....
Important Research News Announcements
- Macrophages influence Schwann cell myelin autophagy after nerve injury and in a model of Charcot-Marie-Tooth disease May 20, 2023
- TGFβ4 alleviates the phenotype of Charcot-Marie-Tooth disease type 1A May 5, 2023
- DGIST Professor Minseok Kim’s team develops an electronic medicine technology that restores abnormal protein behavior, the cause of Charcot-Marie-Tooth Disease (CMT) March 31, 2023
- Charcot-Marie-Tooth neuropathies: current gene therapy advances and the route towards translation March 25, 2023
- MFN2-dependent recruitment of ATAT1 coordinates mitochondria motility with alpha-tubulin acetylation and is disrupted in CMT2A March 17, 2023
- Boosting peripheral BDNF rescues impaired in vivo axonal transport in CMT2D mice March 16, 2023
- Restoring Neurofilaments to Axons in a Mouse Model of CMT2E March 1, 2023
- Full-length isoform sequencing for resolving the molecular basis of Charcot-Marie-Tooth 2A February 8, 2023
- Torin1 restores proliferation rate in Charcot-Marie-Tooth disease type 2A cells harbouring MFN2 (mitofusin 2) mutation February 3, 2023
- Novel Variants in MPV17, PRX, GJB1 , and SACS Cause Charcot-Marie-Tooth and Spastic Ataxia of Charlevoix-Saguenay Type Diseases January 30, 2023